The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL

BJU International

Volumn 110, Issue 3, 2012, Pages 383-390

  Dallas, Nicola L ^a   Malone, Peter R ^a   Jones, Adam ^a   Doggart, Andrew J ^a   McConway, Kevin J ^b   Rogers, Paul B ^a  

^a ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

large prostates; neoadjuvant hormone therapy; prostate cancer; real time brachytherapy; urinary retention

Indexed keywords

BICALUTAMIDE; IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FLOW MEASUREMENT; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; REAL TIME BRACHYTHERAPY; RECTUM DISEASE; RECTUM HEMORRHAGE; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME; URETHRA STRICTURE; URINE RETENTION;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECTAL DISEASES; RISK FACTORS; TUMOR BURDEN; URETHRAL STRICTURE; URINARY RETENTION;

EID: 84863720468     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.10931.x     Document Type: Article

References (32)

1. Kupelian PA, Potters L, Khuntia D, et al,. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25-33 (Pubitemid 38010333)
2. Alicikus ZA, Yamada Y, Zhang Z, et al,. Ten-Year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2010; 117: 1429-37
3. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H,. Radical prostatectomy for clinically advanced (ct3) prostate cancer since the advent of prostate-specific antigen testing: 15-Year outcome. BJU Int 2005; 95: 751-6 (Pubitemid 40547200)
4. Hu JC, Gu X, Lipsitz SR, et al,. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009; 302: 1557-64
5. 3: dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 2000; 46: 1199-204 (Pubitemid 30139431)
6. Nag S, Beyer D, Friedland J, Grimm P, Nath R,. American brachytherapy society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-99 (Pubitemid 29284127)
7. Stock RG, Stone NN, Wesson MF, DeWyngaert JK,. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995; 32: 219-25
8. Stone NN, Chircus JH, Stock RG, Presser J, ProSeed,. The ProSeed approach: a multicenter study of the results of brachytherapy training. In, Dicker AP, Merrick GS, Waterman FM, Valicenti RK, Gomella LG, eds, Basic and Advanced Techniques in Prostate Brachytherapy, 1st edn. Abingdon: Taylor & Francis, 2005: 197-204
9. Salembier C, Lavagnini P, Nickers P, et al,. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007; 83: 3-10 (Pubitemid 46527942)
10. Roach M, Hanks G, Thames H, et al,. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74
11. Consensus statement: Guidelines for PSA following radiation therapy. American society for therapeutic radiology and oncology consensus panel. Int J Radiat Oncol Biol Phys 1997; 37: 1035-41
12. R Development Core Team.). R: A Language and Environment for Statistical Computing. Vienna: Accessed Available at: R Foundation for Statistical Computing, 2010. Available at:. Accessed September 2011
13. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK,. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998; 41: 101-8 (Pubitemid 28211308)
14. 25 prostate brachytherapy in clinically localized prostate cancer: seattle experience. Int J Radiat Oncol Biol Phys 2011; 81: 376-81
15. Crook J, Borg J, Evans A, et al,. 10-Year experience with I-125 prostate brachytherapy at the princess margaret hospital: results for 1,100 patients. Int J Radiat Oncol Biol Phys 2011; 80: 1323-31
16. Ali I, Algan O, Thompson S, et al,. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy. Phys Med Biol 2009; 54: 5595-611
17. 25permanent prostate brachytherapy from a UK multi-institutional database. Clin Oncol (R Coll Radiol) 2008; 20: 738-44
18. Al-Qaisieh B, Witteveen T, Carey B, et al,. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 75: 626-30
19. Meyer JP, Bell CR, Elwell C, Kunkler RB,. Brachytherapy for prostate cancer: is the pretreatment prostate volume important? BJU Int 2008; 102: 1585-8
20. Stone NN, Hong S, Lo YC, Howard V, Stock RG,. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Brachytherapy 2003; 2: 17-25 (Pubitemid 37329402)
21. Lehrer S, Stone NN, Stock RG,. Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy. J Urol 2005; 173: 79-81 (Pubitemid 39627677)
22. Quan AL, Ciezki JP, Reddy CA, et al,. Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate. Urology 2006; 68: 1237-41 (Pubitemid 44880369)
23. 25I seed implantation. Int J Radiat Oncol Biol Phys 2004; 58: 292-9 (Pubitemid 38010365)
24. Acher PL, Popert R, Morris SL, et al,. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation. BJU Int 2007; 99: 1066-71 (Pubitemid 46587897)
25. Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M,. Factors influencing risk of acute urinary retention after trus-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 453-60 (Pubitemid 34170850)
26. Pardo Y, Guedea F, Aguilõ F, et al,. Quality-Of-Life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010; 28: 4687-96
27. Catalona WJ, Carvalhal GF, Mager DE, Smith DS,. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999; 162: 433-8 (Pubitemid 29434355)
28. Ploussard G, de la Taille A, Xylinas E, et al,. Prospective evaluation of combined oncological and functional outcomes after laparoscopic radical prostatectomy: trifecta rate of achieving continence, potency and cancer control at 2 years. BJU Int 2011; 107: 274-9
29. Lee HK, Adams MT, Shi Q, et al,. Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 76: 1445-9
30. Petit JH, Gluck C, Kiger WS, et al,. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. Brachytherapy 2007; 6: 267-71 (Pubitemid 350030634)
31. Sacco DE, Daller M, Grocela JA, Babayan RK, Zietman AL,. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. BJU Int 2003; 91: 345-9 (Pubitemid 36359639)
32. Ohashi T, Yorozu A, Toya K, Saito S, Momma T,. Predictive factors of acute urinary retention requiring catheterization following 125I prostate brachytherapy. Jpn J Clin Oncol 2006; 36: 285-9 (Pubitemid 43997333)